Credit: Shutterstock
December 11, 2024 07:00 AM EST
Deals
Bioregnum
R&D
China
Pharma
FDA+

The End­points 100: The biotech in­dus­try braces for Trump 2.0

John Carroll

Editor & Founder

Big changes are afoot at the FDA in the wake of Don­ald Trump’s re­elec­tion, and there’s con­sid­er­able anx­i­ety in se­nior biotech ranks that an up­heaval …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times